Supplementary table 2. Inclusion/Exclusion criteria

Study
Inclusion Exclusion APPENDIX-AMI [13, 14] De novo lesions, ≥3 mm Ø Cardiogenic shock, stent thrombosis, restenotic lesions, unprotected left main, planned surgery within 12 months, oral anticoagulation, increased risk of bleeding, intolerance of or suspected noncompliance with long-term antiplatelet therapy
BASKET-PROVE [15]
Age ≥ 18 years, chronic total occlusion ≥ 1 month Q wave or non-Q wave myocardial infarction (MI) within the preceding 30 days in the region of the artery to be dilated, LVEF <35%, creatinine >3.0 mg/dl CATOS [16] TIMI flow grade 0 or 1, duration ≥2 weeks, evidence of (silent) ischaemia AMI within 72 hours, LVEF<30%, chronic anticoagulation therapy, a known hypersensitivity or contraindication to aspirin, paclitaxel, either heparin or bivalirudin, clopidogrel or ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated, has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis), known renal insufficiency, history of coagulopathy, CVA or TIA within past 6 months.
ISAR-TEST-2 [28,29]
18 years with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥50% de novo stenosis located in native coronary vessels Key exclusion criteria included patients with target lesion located in the left main stem, in-stent restenosis, cardiogenic shock, malignancies or other comorbid conditions with life expectancy <12 months, known allergy to the study medications (aspirin, clopidogrel, sirolimus, stainless steel), or pregnancy or positive pregnancy test.
KOMER [30]
ST-elevation myocardial infarction, >18 years, stenosis >50%, ≥2.5 mm and ≤4.0 mm Ø, de novo native coronary artery lesion All-comer population Participation in ongoing study, planned surgery < 6 months after procedure
RESET [36]
Patients scheduled for PCI with DES NA Sakakibara et al. [37] Patients on maintenance hemodialysis with stable angina pectoris who underwent PCI for native coronary lesions with a maximum of 2 de novo coronary artery lesions with length <30 mm and vessel diameter ≥2.5-≤4.0 mm.
None listed
Sawada et al. [38]
patients presenting with symptoms of acute myocardial infarction b24 h before arrival at the catheterization laboratory; 2) total creatinine kinase (CK) or CK-MB greater than twice the upper limit of our hospital's laboratory normal; 3) the ECG revealed a ST segment elevation>0.1 mV in 2 continuous leads Patients with multivessel disease or chronic total occlusion requiring coronary artery bypass grafting surgery, patients presenting with a culprit lesion where the reference external elastic membrane diameter was >4.0 mm, patients presenting with a culprit lesion where the reference external elastic membrane diameter was b2.5 mm, measured by intravascular ultrasound (IVUS), patients whose culprit lesion was judged unsuitable for OCT and angioscopy procedure, because of conditions such as left main trunk disease or shock vital, patients with severe dementia that increased risk of difficulty in follow-up angiography.
SEA-SIDE [39]
≥18 years Contraindication for prolonged DAPT, hypersensitivity to sirolimus, everolimus, cobalt, chromium, nickel, tungsten acrylic, and fluoropolymers, STEMI <48h
SEZE [40]
18 years or older and diagnosed with STEMI, which was defined as chest pain of less than 12 hours duration with ST-segment elevation more than 0.1 mV in at least two contiguous leads on electrocardiography Rescue PCI after thrombolysis; patients presenting in cardiogenic shock (defined as persistent systolic blood pressure <90 mmHg or the need for vasopressors or intraaortic balloon pumping to maintain blood pressure >90 mmHg with evidence of end organ failure and elevated left ventricular filling pressures); previous PCI of the infarctrelated artery; significant left main lesion; patients who underwent previous coronary artery bypass graft surgery; patients with contraindication to heparin or dual antiplatelet therapy (aspirin and clopidogrel); patients with history of gastrointestinal or genitourinary bleeding in 3 months; history of major operation in 3 months; and patients with co-morbidities with life expectancy less than 1 year. Patients were also excluded if the culprit lesion was located in a vessel with reference vessel diameter <2.25 mm or >4.0 mm.
Song et al. [41]
All-comer design. patients were consecutively enrolled with stable angina or acute coronary syndrome or inducible ischemia in the presence of restenosis >50% diameter stenosis in the stented segment with or without edge involvement by quantitative coronary angiography Acute ST-segment elevation myocardial infarction (MI) necessitating primary percutaneous coronary intervention; severely compromised ventricular dysfunction (ejection fraction <30%) or cardiogenic shock; allergy to antiplatelet drugs, heparin, stainless steel, contrast agents, everolimus or sirolimus; left main coronary artery disease (defined as stenosis of >50%); chronic renal failure (serum creatinine level >2.0 mg/dl or dependence on dialysis); terminal illness; elective surgery planned within 6 months after the procedure, necessitating discontinuation of antiplatelet agent; participation in another coronary device study or inability to follow the protocol.
SORT OUT III [42,43]
≥18 years, chronic stable coronary artery disease or acute coronary syndromes, at least 1 coronary artery lesion with more than 50% diameter stenosis needing treatment with DES Life expectancy <1 year, allergy to aspirin, clopidogrel, ticlopidine, sirolimus, or zotarolimus; participation in other randomised trial, inability to provide written informed consent SORT OUT IV [44,45] ≥18 years, chronic stable coronary artery disease or acute coronary syndromes, at least 1 coronary artery lesion with more than 50% diameter stenosis needing treatment with DES Life expectancy <1 year, allergy to aspirin, clopidogrel, sirolimus, or everolimus, participation in other randomised trial, inability to provide written informed consent
SPIRIT II [46,47]
2.5-4.25 mm Ø, <28 mm lesion length, estimated stenosis 50-99%, TIMI flow ≥1
Acute myocardial infarction <3 days of baseline procedure, LVEF <30%, awaiting heart transplantation, known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, clopidogrel or ticlopidine, cobalt, chromium, nickel, tungsten, everolimus, paclitaxel, acrylic and fluoropolymers, aorto-ostial or left main stem lesions, <2 mm Ø of the origin of LAD or RCX, heavy calcification, visible thrombus SPIRIT III [48,49] 1 or 2 de novo native coronary artery lesions, maximum 1 lesion per epicardial coronary artery, ≥18 years, stable or unstable angina or inducible ischaemia PCI in the target vessel before or planned within 9 months after the index procedure or in a non-target vessel within 90 days before or planned within 9 months afterward, acute or recent myocardial infarction, LVEF <30%, use of long-term anticoagulation, recent major bleed, haemorrhagic diathesis, or objection to blood transfusions; contraindications for or allergy to any of the study medications, components of the study stents, or iodinated contrast that could not be pre-medicated; elective surgery planned within 9 months after the procedure necessitating discontinuation of antiplatelet agents; platelet count <100 000 or >700 000 cells/mm 3 , white blood cell count <3000 cells/mm 3 , serum creatinine >2.5 mg/dL, dialysis, or liver disease; stroke or transient ischaemic attack within 6 months; comorbid conditions limiting life expectancy <1 year or that could affect protocol compliance; participation in another investigational study that has not yet reached its primary end point SPIRIT IV [50, 51] Up to 3 previously untreated native coronary arteries, lesion length ≤28 mm, between 2.5 and 3.75 mm Ø, lesion length ≤28 mm. >50% stenosis, TIMI flow ≥1 
